

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 10665

Table 1.--Testing Results "FORDS" Study Psychostimulants

[Survey Period - May 1972-September 1972]

Manufacturer	Declared potency (mg.)	Number batches sampled and analyzed	Number defective samples
<u>Amitriptyline HCl Tablets:</u>			
Merck Sharp & Dohme.....	10.0	3	0
	25.0	3	0
	50.0	<u>3</u>	<u>0</u>
Totals.....		9	0
<u>Amitriptyline HCl Injection:</u>			
Merck Sharp & Dohme.....	10.0 mg/ml	<u>2</u>	<u>0</u>
Totals.....		2	0
<u>Desipramine HCl Tablets:</u>			
K-V Pharmacal	25.0	2	0
	50.0	<u>3</u>	<u>0</u>
Totals.....		5	0
<u>Desipramine HCl Capsules:</u>			
U.S. Vitamin	25.0	4	0
	50.0	<u>1</u>	<u>0</u>
Totals.....		5	0
<u>Imipramine HCl Tablets:</u>			
Ciba-Geigy Corp.	10.0	2	0
	25.0	1	0
	50.0	<u>3</u>	<u>0</u>
Totals.....		6	0
<u>Nortriptyline HCl Capsules:</u>			
Eli Lilly & Company.....	10.0	3	0
	25.0	<u>6</u>	<u>0</u>
Totals.....		9	0
<u>Protriptyline HCl Tablets:</u>			
Merck Sharp & Dohme.....	5.0	3	0
	10.0	<u>3</u>	<u>0</u>
Totals.....		6	0